ANZCTR search results

The aim of this study is to determine the feasibility, safety, and acceptability of short-term humidified flow therapy (myAirvo 3TM) in people living with respiratory conditions in the SESLHD community. The hypothesis is that myAirvo 3 is feasible, safe and acceptable to be used in the community and will assist sputum burden and/or breathlessness.

This study is investigating whether routine heart monitoring during treatment with HER2-directed therapies for patients with breast cancer can be simplified. Who is it for? You may be eligible for this study if you are aged 18 years or older, you have been diagnosed with HER2-positive breast cancer and will be undergoing treatment for your cancer that is targeted at the HER2-cancer cell receptors. Study details All participants who choose to enrol in this study will be randomly allocated by chance (similar to flipping a coin) to one of four groups. Participants allocated to the first group will be asked to attend the standard heart care monitoring (full scanning protocol) every 3 months for one year. Participants allocated to the second group will be asked to attend a shorter scanning protocol (abbreviated protocol) every 3 months for one year. Participants allocated to the third and fourth groups will be asked to attend either the full scanning protocol or the abbreviated protocol, but only every 6 months for one year. It is hoped this research will determine whether fewer surveillance monitoring visits are still able to detect any changes in heart health for patients with breast cancer. If this study does indicate that fewer monitoring visits are safe, it could reduce the burden associated with cancer care on patients with breast cancer.

This trial is evaluating a new imaging method, XV LVAS, which generates a 4D report of lung structure and function. This will be used to evaluate the increase in lung function reported in children with cystic fibrosis when starting the modulator therapy ETI (elexacaftor/tezacaftor/ivacaftor). Standard lung function tests will be compared to XV LVAS scan before and after commencement of ETI treatment. This will demonstrate the safety and clinical utility of XV LVAS scans in children and further characterise the improvement of lung function on commencement of ETI therapy.

Neonatal stroke occurs in up to 1 in 2,500 live births and can be defined as disturbances in the blood supply to the brain and includes an acute ischemic event. Up to 60% of babies diagnosed with stroke will have atypical neurological development and brain injury, including epilepsy and cerebral palsy. Current standard of care focusses on diagnosis and prompt stabilisation of symptoms such as seizures. There are no specific interventions to protect the developing brain or prevent the progression of injury. However, stem cells, particularly mesenchymal stem cells (MSCs), are a potential treatment for neonatal stroke, where early therapy may minimise lifelong impairment. This Phase I dose escalation trial assesses the safety of early and repeated systemic (intravenous) administration of MSCs for neonatal stroke at both 2- and 5-million cells/kg body weight.

Despite the substantial volume of bifurcation PCI which is performed in ANZ, there is no local registry in which procedural techniques, device usage, and outcomes are documented. The study is observational in nature only, with PCI selection and technique will be left at the discretion of the operator. Eligible subjects will be enrolled into the registry after providing informed consent. Medical records review and phone call follow up will be performed to assess for the incidence of the primary and secondary outcome at 72hrs (medical record only), 3 months, 1 year and 2 years.

The purpose of this study is to develop and test a transitional model of care coordination to optimally support people living with multimorbidity, post-hospital discharge, via telehealth, and ensure continuity of care between the secondary (acute) and primary healthcare sectors to minimise direct contact with hospital services. The intervention will be a 6-8 week care coordination support from 'STARnurses' for 6 -8 weeks post-hospital discharge. We hypothesise that the provision of a transition support service, post-hospital discharge, for patients with multimorbidity will decrease the short-term hospital readmission rate for that patient cohort.

This is an investigational combination treatment arm within the ALLG AMLM26 INTERCEPT trial platform, which is registered on ANZCTR with ID ACTRN12621000439842. This treatment arm (Ivosidenib + Venetoclax) will be evaluated for its activity in a population of participants with progressive acute myeloid leukemia (AML). Who is it for? You may be eligible for to receive this treatment if you are a part of the AMLM26 Intercept trial which is registered on ANZCTR with ID ACTRN12621000439842 (ie if you are aged 18 or older, you have been diagnosed with progressive acute myeloid leukemia, and are currently in your first or second morphologic remission with a known and trackable minimal residual disease (MRD) marker.). If you are on the AMLM26 Intercept trial you may be eligible for this treatment option if your disease is worsening. The trial management committee will review your disease characteristics and determine your best treatment option(s) available on the trial. Study details Ivosidenib and Venetoclax are given orally. Ivosidenib 500mg once a day commencing day 15 of cycle one and taken continuously and Venetoclax administered days 1-14 of a 28 day cycle for 12 cycles. Patients with minimal residual disease will have a pilot safety run-in phase to confirm dose - investigating Venetoclax doses 800mg or 600mg daily. Once a tolerable dose is determined that dose will be used in a proof of concept phase.. Patients with morphologic relapse will enter directly into a proof of concept phase using a Venetoclax dose of 800mg daily with a dose ramp up in cycle 1. Participants will undergo a disease assessment at screening after cycle 1, cycle 2, cycle 3, cycle 6 and then 2 monthly until progression. This will require blood tests and bone marrow biopsies. Safety and tolerability of treatment will be assessed throughout the trial whilst you are receiving treatment. Health related quality of life during treatment will be assessed on the first treatment day of 3 consecutive cycles. This study is being carried out to improve the way we treat cancer patients who may have limited treatment options available to them. It is hoped that Ivosidenib and Venetoclax will be well tolerated and may improve outcomes for future patients, however, there may be no clear benefit from participation in this study.

Examining all intubated patients presenting with drug overdose to GCHHS EDs. Retrospective cohort study. Descriptive. Low risk from ethics perspective. Data collection from Feb 2021 to Sept 2023.

The Powerful Pictures study is an ambitious project which seeks to partner with First Nations Australians to co-design a new, improved model of care to identify and manage heart disease in patients at risk of future heart attacks. This model of care includes increasing access to a high-quality imaging test, Computed Tomography Coronary Angiography (CTCA) for the detection of early heart disease. The Powerful Pictures model of care will be co-designed with local communities, patients with lived experience of a possible heart attack, local clinicians, health workers, and health services managers and leadership. The model will then be implemented in regional (Cairns), outer regional (Atherton and Mareeba) and remote (Weipa) hospitals across Far North Queensland

The aim of this study is to address the knowledge gaps relating to prehabilitation in older frail patients having hip or knee surgery, and to explore the opportunities of delivering home-based preoperative care through digital technology. Patients will be randomly allocated to a treatment group. One group will receive standard preoperative care before their surgery. The other group will receive standard care plus the prehabilitation program before their surgery. This study also acts to inform future research in frail patients undergoing these surgeries to optimise post-operative outcomes.